Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Stoke Therapeutics +3.36% Pre
Stoke Therapeutics STOK | 12.31 12.31 | +3.36% 0.00% Pre |
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:
STOK) with a Buy and maintains $22 price target.